Dr. Kanakry is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Johns Hopkins Hospital
600 N Wolfe Street
Baltimore, MD 21287Phone+1 410-955-5000
Education & Training
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2010 - 2013- Johns Hopkins UniversityResidency, Internal Medicine, 2007 - 2010
Duke University School of MedicineClass of 2007
Certifications & Licensure
MD State Medical License 2010 - 2026- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
Clinical Trials
- Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies Start of enrollment: 2021 Sep 23
Roles: Principal Investigator, Contact
- Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies Start of enrollment: 2022 May 23
Roles: Contact, Principal Investigator
- Optimizing PTCy Dose and Timing Start of enrollment: 2019 Jul 09
Roles: Principal Investigator, Contact
- Join now to see all
Publications & Presentations
PubMed
- 151 citationsDonor CD4+ Foxp3+ regulatory T cells are necessary for posttransplantation cyclophosphamide-mediated protection against GVHD in mice.Sudipto Ganguly, Duncan B. Ross, Angela Panoskaltsis-Mortari, Christopher G. Kanakry, Bruce R. Blazar
Blood. 2014-09-25 - 16 citationsPosttransplantation cyclophosphamide expands functional myeloid-derived suppressor cells and indirectly influences Tregs.Rochelle E Fletcher, Natalia S Nunes, Michael T Patterson, Natasha Vinod, Shanzay M Khan
Blood Advances. 2023-04-11 - 57 citationsModern approaches to HLA-haploidentical blood or marrow transplantation.Christopher G Kanakry, Ephraim J Fuchs, Leo Luznik
Nature Reviews. Clinical Oncology. 2016-01-01
Press Mentions
Drug Regimen Enough to Control Immune Disease After Some Bone Marrow TransplantsOctober 8th, 2014- How Common Chemo Drug Thwarts Graft Rejection in Bone Marrow TransplantsNovember 13th, 2013
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
